Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Multiple Myeloma

NCT06106945 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06106945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06106945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Multiple Myeloma
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 5, 2023
Completion date
August 16, 2027
Enrollment
226 (estimated)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma